Sunshine Biopharma (SBFM) has released an update.
Sunshine Biopharma has reported a significant 54% increase in revenue to $7.54 million in the first quarter of 2024, compared to the same period last year, driven by new product launches and marketing efforts. Despite the revenue growth, the company experienced a net loss of $1.28 million, which is an improvement over the previous year’s $1.70 million loss. Sunshine Biopharma continues to expand its portfolio with new drug launches planned for 2024 and 2025, including a biosimilar to NEULASTA®.
For further insights into SBFM stock, check out TipRanks’ Stock Analysis page.
